Medical Care
Global Respiratory Syncytial Virus Vaccines Market Research Report 2025
- Mar 27, 25
- ID: 164223
- Pages: 88
- Figures: 90
- Views: 41
The global market for Respiratory Syncytial Virus Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus Vaccines.
The Respiratory Syncytial Virus Vaccines market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Syncytial Virus Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Syncytial Virus Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc.Pfizer Inc.
Sanofi
Merck Sharp & Dohme
GlaxoSmithKline
SOBI
Johnson & Johnson
Bavarian Nordic
Novavax
AstraZeneca
Moderna
Codagenix
Intravacc
Alphavax
Segment by Type
Palivizumab
RSVpreF PF06928316
RSVPreF3 OA (GSK3844766A)
mRNA-1345
Janssen RSV Vaccine
ResVax
Nirsevimab (MEDI8897)
MVA-BN RSV
Segment by Application
Hospital
Clinic
Research Institute
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus Vaccines.
The Respiratory Syncytial Virus Vaccines market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Syncytial Virus Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Syncytial Virus Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc.Pfizer Inc.
Sanofi
Merck Sharp & Dohme
GlaxoSmithKline
SOBI
Johnson & Johnson
Bavarian Nordic
Novavax
AstraZeneca
Moderna
Codagenix
Intravacc
Alphavax
Segment by Type
Palivizumab
RSVpreF PF06928316
RSVPreF3 OA (GSK3844766A)
mRNA-1345
Janssen RSV Vaccine
ResVax
Nirsevimab (MEDI8897)
MVA-BN RSV
Segment by Application
Hospital
Clinic
Research Institute
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Palivizumab
1.2.3 RSVpreF PF06928316
1.2.4 RSVPreF3 OA (GSK3844766A)
1.2.5 mRNA-1345
1.2.6 Janssen RSV Vaccine
1.2.7 ResVax
1.2.8 Nirsevimab (MEDI8897)
1.2.9 MVA-BN RSV
1.3 Market by Application
1.3.1 Global Respiratory Syncytial Virus Vaccines Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Syncytial Virus Vaccines Market Perspective (2020-2031)
2.2 Global Respiratory Syncytial Virus Vaccines Growth Trends by Region
2.2.1 Global Respiratory Syncytial Virus Vaccines Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Syncytial Virus Vaccines Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Syncytial Virus Vaccines Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Syncytial Virus Vaccines Market Dynamics
2.3.1 Respiratory Syncytial Virus Vaccines Industry Trends
2.3.2 Respiratory Syncytial Virus Vaccines Market Drivers
2.3.3 Respiratory Syncytial Virus Vaccines Market Challenges
2.3.4 Respiratory Syncytial Virus Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue
3.1.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue (2020-2025)
3.1.2 Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Syncytial Virus Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Syncytial Virus Vaccines Revenue
3.4 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio
3.4.1 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus Vaccines Revenue in 2024
3.5 Global Key Players of Respiratory Syncytial Virus Vaccines Head office and Area Served
3.6 Global Key Players of Respiratory Syncytial Virus Vaccines, Product and Application
3.7 Global Key Players of Respiratory Syncytial Virus Vaccines, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Syncytial Virus Vaccines Breakdown Data by Type
4.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Type (2026-2031)
5 Respiratory Syncytial Virus Vaccines Breakdown Data by Application
5.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
6.2 North America Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
6.4 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
7.2 Europe Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
7.4 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
9.2 Latin America Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
9.4 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.Pfizer Inc.
11.1.1 Pfizer Inc.Pfizer Inc. Company Details
11.1.2 Pfizer Inc.Pfizer Inc. Business Overview
11.1.3 Pfizer Inc.Pfizer Inc. Respiratory Syncytial Virus Vaccines Introduction
11.1.4 Pfizer Inc.Pfizer Inc. Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.1.5 Pfizer Inc.Pfizer Inc. Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Respiratory Syncytial Virus Vaccines Introduction
11.2.4 Sanofi Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.2.5 Sanofi Recent Development
11.3 Merck Sharp & Dohme
11.3.1 Merck Sharp & Dohme Company Details
11.3.2 Merck Sharp & Dohme Business Overview
11.3.3 Merck Sharp & Dohme Respiratory Syncytial Virus Vaccines Introduction
11.3.4 Merck Sharp & Dohme Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.3.5 Merck Sharp & Dohme Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Respiratory Syncytial Virus Vaccines Introduction
11.4.4 GlaxoSmithKline Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 SOBI
11.5.1 SOBI Company Details
11.5.2 SOBI Business Overview
11.5.3 SOBI Respiratory Syncytial Virus Vaccines Introduction
11.5.4 SOBI Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.5.5 SOBI Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Respiratory Syncytial Virus Vaccines Introduction
11.6.4 Johnson & Johnson Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 Bavarian Nordic
11.7.1 Bavarian Nordic Company Details
11.7.2 Bavarian Nordic Business Overview
11.7.3 Bavarian Nordic Respiratory Syncytial Virus Vaccines Introduction
11.7.4 Bavarian Nordic Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.7.5 Bavarian Nordic Recent Development
11.8 Novavax
11.8.1 Novavax Company Details
11.8.2 Novavax Business Overview
11.8.3 Novavax Respiratory Syncytial Virus Vaccines Introduction
11.8.4 Novavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.8.5 Novavax Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Respiratory Syncytial Virus Vaccines Introduction
11.9.4 AstraZeneca Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.9.5 AstraZeneca Recent Development
11.10 Moderna
11.10.1 Moderna Company Details
11.10.2 Moderna Business Overview
11.10.3 Moderna Respiratory Syncytial Virus Vaccines Introduction
11.10.4 Moderna Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.10.5 Moderna Recent Development
11.11 Codagenix
11.11.1 Codagenix Company Details
11.11.2 Codagenix Business Overview
11.11.3 Codagenix Respiratory Syncytial Virus Vaccines Introduction
11.11.4 Codagenix Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.11.5 Codagenix Recent Development
11.12 Intravacc
11.12.1 Intravacc Company Details
11.12.2 Intravacc Business Overview
11.12.3 Intravacc Respiratory Syncytial Virus Vaccines Introduction
11.12.4 Intravacc Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.12.5 Intravacc Recent Development
11.13 Alphavax
11.13.1 Alphavax Company Details
11.13.2 Alphavax Business Overview
11.13.3 Alphavax Respiratory Syncytial Virus Vaccines Introduction
11.13.4 Alphavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.13.5 Alphavax Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Palivizumab
1.2.3 RSVpreF PF06928316
1.2.4 RSVPreF3 OA (GSK3844766A)
1.2.5 mRNA-1345
1.2.6 Janssen RSV Vaccine
1.2.7 ResVax
1.2.8 Nirsevimab (MEDI8897)
1.2.9 MVA-BN RSV
1.3 Market by Application
1.3.1 Global Respiratory Syncytial Virus Vaccines Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Syncytial Virus Vaccines Market Perspective (2020-2031)
2.2 Global Respiratory Syncytial Virus Vaccines Growth Trends by Region
2.2.1 Global Respiratory Syncytial Virus Vaccines Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Syncytial Virus Vaccines Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Syncytial Virus Vaccines Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Syncytial Virus Vaccines Market Dynamics
2.3.1 Respiratory Syncytial Virus Vaccines Industry Trends
2.3.2 Respiratory Syncytial Virus Vaccines Market Drivers
2.3.3 Respiratory Syncytial Virus Vaccines Market Challenges
2.3.4 Respiratory Syncytial Virus Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue
3.1.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue (2020-2025)
3.1.2 Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Syncytial Virus Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Syncytial Virus Vaccines Revenue
3.4 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio
3.4.1 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus Vaccines Revenue in 2024
3.5 Global Key Players of Respiratory Syncytial Virus Vaccines Head office and Area Served
3.6 Global Key Players of Respiratory Syncytial Virus Vaccines, Product and Application
3.7 Global Key Players of Respiratory Syncytial Virus Vaccines, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Syncytial Virus Vaccines Breakdown Data by Type
4.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Type (2026-2031)
5 Respiratory Syncytial Virus Vaccines Breakdown Data by Application
5.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
6.2 North America Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
6.4 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
7.2 Europe Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
7.4 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
9.2 Latin America Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
9.4 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.Pfizer Inc.
11.1.1 Pfizer Inc.Pfizer Inc. Company Details
11.1.2 Pfizer Inc.Pfizer Inc. Business Overview
11.1.3 Pfizer Inc.Pfizer Inc. Respiratory Syncytial Virus Vaccines Introduction
11.1.4 Pfizer Inc.Pfizer Inc. Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.1.5 Pfizer Inc.Pfizer Inc. Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Respiratory Syncytial Virus Vaccines Introduction
11.2.4 Sanofi Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.2.5 Sanofi Recent Development
11.3 Merck Sharp & Dohme
11.3.1 Merck Sharp & Dohme Company Details
11.3.2 Merck Sharp & Dohme Business Overview
11.3.3 Merck Sharp & Dohme Respiratory Syncytial Virus Vaccines Introduction
11.3.4 Merck Sharp & Dohme Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.3.5 Merck Sharp & Dohme Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Respiratory Syncytial Virus Vaccines Introduction
11.4.4 GlaxoSmithKline Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 SOBI
11.5.1 SOBI Company Details
11.5.2 SOBI Business Overview
11.5.3 SOBI Respiratory Syncytial Virus Vaccines Introduction
11.5.4 SOBI Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.5.5 SOBI Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Respiratory Syncytial Virus Vaccines Introduction
11.6.4 Johnson & Johnson Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 Bavarian Nordic
11.7.1 Bavarian Nordic Company Details
11.7.2 Bavarian Nordic Business Overview
11.7.3 Bavarian Nordic Respiratory Syncytial Virus Vaccines Introduction
11.7.4 Bavarian Nordic Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.7.5 Bavarian Nordic Recent Development
11.8 Novavax
11.8.1 Novavax Company Details
11.8.2 Novavax Business Overview
11.8.3 Novavax Respiratory Syncytial Virus Vaccines Introduction
11.8.4 Novavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.8.5 Novavax Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Respiratory Syncytial Virus Vaccines Introduction
11.9.4 AstraZeneca Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.9.5 AstraZeneca Recent Development
11.10 Moderna
11.10.1 Moderna Company Details
11.10.2 Moderna Business Overview
11.10.3 Moderna Respiratory Syncytial Virus Vaccines Introduction
11.10.4 Moderna Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.10.5 Moderna Recent Development
11.11 Codagenix
11.11.1 Codagenix Company Details
11.11.2 Codagenix Business Overview
11.11.3 Codagenix Respiratory Syncytial Virus Vaccines Introduction
11.11.4 Codagenix Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.11.5 Codagenix Recent Development
11.12 Intravacc
11.12.1 Intravacc Company Details
11.12.2 Intravacc Business Overview
11.12.3 Intravacc Respiratory Syncytial Virus Vaccines Introduction
11.12.4 Intravacc Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.12.5 Intravacc Recent Development
11.13 Alphavax
11.13.1 Alphavax Company Details
11.13.2 Alphavax Business Overview
11.13.3 Alphavax Respiratory Syncytial Virus Vaccines Introduction
11.13.4 Alphavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025)
11.13.5 Alphavax Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Palivizumab
Table 3. Key Players of RSVpreF PF06928316
Table 4. Key Players of RSVPreF3 OA (GSK3844766A)
Table 5. Key Players of mRNA-1345
Table 6. Key Players of Janssen RSV Vaccine
Table 7. Key Players of ResVax
Table 8. Key Players of Nirsevimab (MEDI8897)
Table 9. Global Respiratory Syncytial Virus Vaccines Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Respiratory Syncytial Virus Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Respiratory Syncytial Virus Vaccines Market Share by Region (2020-2025)
Table 13. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Respiratory Syncytial Virus Vaccines Market Share by Region (2026-2031)
Table 15. Respiratory Syncytial Virus Vaccines Market Trends
Table 16. Respiratory Syncytial Virus Vaccines Market Drivers
Table 17. Respiratory Syncytial Virus Vaccines Market Challenges
Table 18. Respiratory Syncytial Virus Vaccines Market Restraints
Table 19. Global Respiratory Syncytial Virus Vaccines Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Respiratory Syncytial Virus Vaccines Market Share by Players (2020-2025)
Table 21. Global Top Respiratory Syncytial Virus Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccines as of 2024)
Table 22. Ranking of Global Top Respiratory Syncytial Virus Vaccines Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Respiratory Syncytial Virus Vaccines Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Respiratory Syncytial Virus Vaccines, Headquarters and Area Served
Table 25. Global Key Players of Respiratory Syncytial Virus Vaccines, Product and Application
Table 26. Global Key Players of Respiratory Syncytial Virus Vaccines, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Respiratory Syncytial Virus Vaccines Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Type (2020-2025)
Table 30. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Type (2026-2031)
Table 32. Global Respiratory Syncytial Virus Vaccines Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Application (2020-2025)
Table 34. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Application (2026-2031)
Table 36. North America Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 51. Pfizer Inc.Pfizer Inc. Company Details
Table 52. Pfizer Inc.Pfizer Inc. Business Overview
Table 53. Pfizer Inc.Pfizer Inc. Respiratory Syncytial Virus Vaccines Product
Table 54. Pfizer Inc.Pfizer Inc. Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 55. Pfizer Inc.Pfizer Inc. Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Respiratory Syncytial Virus Vaccines Product
Table 59. Sanofi Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. Merck Sharp & Dohme Company Details
Table 62. Merck Sharp & Dohme Business Overview
Table 63. Merck Sharp & Dohme Respiratory Syncytial Virus Vaccines Product
Table 64. Merck Sharp & Dohme Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 65. Merck Sharp & Dohme Recent Development
Table 66. GlaxoSmithKline Company Details
Table 67. GlaxoSmithKline Business Overview
Table 68. GlaxoSmithKline Respiratory Syncytial Virus Vaccines Product
Table 69. GlaxoSmithKline Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 70. GlaxoSmithKline Recent Development
Table 71. SOBI Company Details
Table 72. SOBI Business Overview
Table 73. SOBI Respiratory Syncytial Virus Vaccines Product
Table 74. SOBI Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 75. SOBI Recent Development
Table 76. Johnson & Johnson Company Details
Table 77. Johnson & Johnson Business Overview
Table 78. Johnson & Johnson Respiratory Syncytial Virus Vaccines Product
Table 79. Johnson & Johnson Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 80. Johnson & Johnson Recent Development
Table 81. Bavarian Nordic Company Details
Table 82. Bavarian Nordic Business Overview
Table 83. Bavarian Nordic Respiratory Syncytial Virus Vaccines Product
Table 84. Bavarian Nordic Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 85. Bavarian Nordic Recent Development
Table 86. Novavax Company Details
Table 87. Novavax Business Overview
Table 88. Novavax Respiratory Syncytial Virus Vaccines Product
Table 89. Novavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 90. Novavax Recent Development
Table 91. AstraZeneca Company Details
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Respiratory Syncytial Virus Vaccines Product
Table 94. AstraZeneca Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 95. AstraZeneca Recent Development
Table 96. Moderna Company Details
Table 97. Moderna Business Overview
Table 98. Moderna Respiratory Syncytial Virus Vaccines Product
Table 99. Moderna Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 100. Moderna Recent Development
Table 101. Codagenix Company Details
Table 102. Codagenix Business Overview
Table 103. Codagenix Respiratory Syncytial Virus Vaccines Product
Table 104. Codagenix Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 105. Codagenix Recent Development
Table 106. Intravacc Company Details
Table 107. Intravacc Business Overview
Table 108. Intravacc Respiratory Syncytial Virus Vaccines Product
Table 109. Intravacc Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 110. Intravacc Recent Development
Table 111. Alphavax Company Details
Table 112. Alphavax Business Overview
Table 113. Alphavax Respiratory Syncytial Virus Vaccines Product
Table 114. Alphavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 115. Alphavax Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Respiratory Syncytial Virus Vaccines Picture
Figure 2. Global Respiratory Syncytial Virus Vaccines Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Syncytial Virus Vaccines Market Share by Type: 2024 VS 2031
Figure 4. Palivizumab Features
Figure 5. RSVpreF PF06928316 Features
Figure 6. RSVPreF3 OA (GSK3844766A) Features
Figure 7. mRNA-1345 Features
Figure 8. Janssen RSV Vaccine Features
Figure 9. ResVax Features
Figure 10. Nirsevimab (MEDI8897) Features
Figure 11. MVA-BN RSV Features
Figure 12. Global Respiratory Syncytial Virus Vaccines Market Size by Application (2020-2031) & (US$ Million)
Figure 13. Global Respiratory Syncytial Virus Vaccines Market Share by Application: 2024 VS 2031
Figure 14. Hospital Case Studies
Figure 15. Clinic Case Studies
Figure 16. Research Institute Case Studies
Figure 17. Respiratory Syncytial Virus Vaccines Report Years Considered
Figure 18. Global Respiratory Syncytial Virus Vaccines Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Respiratory Syncytial Virus Vaccines Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Respiratory Syncytial Virus Vaccines Market Share by Region: 2024 VS 2031
Figure 21. Global Respiratory Syncytial Virus Vaccines Market Share by Players in 2024
Figure 22. Global Top Respiratory Syncytial Virus Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccines as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Respiratory Syncytial Virus Vaccines Revenue in 2024
Figure 24. North America Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 26. United States Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 30. Germany Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Share by Region (2020-2031)
Figure 38. China Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 46. Mexico Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 50. Turkey Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Pfizer Inc.Pfizer Inc. Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 55. Merck Sharp & Dohme Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 56. GlaxoSmithKline Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 57. SOBI Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 58. Johnson & Johnson Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 59. Bavarian Nordic Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 60. Novavax Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 61. AstraZeneca Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 62. Moderna Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 63. Codagenix Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 64. Intravacc Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 65. Alphavax Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Palivizumab
Table 3. Key Players of RSVpreF PF06928316
Table 4. Key Players of RSVPreF3 OA (GSK3844766A)
Table 5. Key Players of mRNA-1345
Table 6. Key Players of Janssen RSV Vaccine
Table 7. Key Players of ResVax
Table 8. Key Players of Nirsevimab (MEDI8897)
Table 9. Global Respiratory Syncytial Virus Vaccines Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Respiratory Syncytial Virus Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Respiratory Syncytial Virus Vaccines Market Share by Region (2020-2025)
Table 13. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Respiratory Syncytial Virus Vaccines Market Share by Region (2026-2031)
Table 15. Respiratory Syncytial Virus Vaccines Market Trends
Table 16. Respiratory Syncytial Virus Vaccines Market Drivers
Table 17. Respiratory Syncytial Virus Vaccines Market Challenges
Table 18. Respiratory Syncytial Virus Vaccines Market Restraints
Table 19. Global Respiratory Syncytial Virus Vaccines Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Respiratory Syncytial Virus Vaccines Market Share by Players (2020-2025)
Table 21. Global Top Respiratory Syncytial Virus Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccines as of 2024)
Table 22. Ranking of Global Top Respiratory Syncytial Virus Vaccines Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Respiratory Syncytial Virus Vaccines Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Respiratory Syncytial Virus Vaccines, Headquarters and Area Served
Table 25. Global Key Players of Respiratory Syncytial Virus Vaccines, Product and Application
Table 26. Global Key Players of Respiratory Syncytial Virus Vaccines, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Respiratory Syncytial Virus Vaccines Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Type (2020-2025)
Table 30. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Type (2026-2031)
Table 32. Global Respiratory Syncytial Virus Vaccines Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Application (2020-2025)
Table 34. Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Application (2026-2031)
Table 36. North America Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 51. Pfizer Inc.Pfizer Inc. Company Details
Table 52. Pfizer Inc.Pfizer Inc. Business Overview
Table 53. Pfizer Inc.Pfizer Inc. Respiratory Syncytial Virus Vaccines Product
Table 54. Pfizer Inc.Pfizer Inc. Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 55. Pfizer Inc.Pfizer Inc. Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Respiratory Syncytial Virus Vaccines Product
Table 59. Sanofi Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. Merck Sharp & Dohme Company Details
Table 62. Merck Sharp & Dohme Business Overview
Table 63. Merck Sharp & Dohme Respiratory Syncytial Virus Vaccines Product
Table 64. Merck Sharp & Dohme Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 65. Merck Sharp & Dohme Recent Development
Table 66. GlaxoSmithKline Company Details
Table 67. GlaxoSmithKline Business Overview
Table 68. GlaxoSmithKline Respiratory Syncytial Virus Vaccines Product
Table 69. GlaxoSmithKline Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 70. GlaxoSmithKline Recent Development
Table 71. SOBI Company Details
Table 72. SOBI Business Overview
Table 73. SOBI Respiratory Syncytial Virus Vaccines Product
Table 74. SOBI Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 75. SOBI Recent Development
Table 76. Johnson & Johnson Company Details
Table 77. Johnson & Johnson Business Overview
Table 78. Johnson & Johnson Respiratory Syncytial Virus Vaccines Product
Table 79. Johnson & Johnson Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 80. Johnson & Johnson Recent Development
Table 81. Bavarian Nordic Company Details
Table 82. Bavarian Nordic Business Overview
Table 83. Bavarian Nordic Respiratory Syncytial Virus Vaccines Product
Table 84. Bavarian Nordic Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 85. Bavarian Nordic Recent Development
Table 86. Novavax Company Details
Table 87. Novavax Business Overview
Table 88. Novavax Respiratory Syncytial Virus Vaccines Product
Table 89. Novavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 90. Novavax Recent Development
Table 91. AstraZeneca Company Details
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Respiratory Syncytial Virus Vaccines Product
Table 94. AstraZeneca Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 95. AstraZeneca Recent Development
Table 96. Moderna Company Details
Table 97. Moderna Business Overview
Table 98. Moderna Respiratory Syncytial Virus Vaccines Product
Table 99. Moderna Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 100. Moderna Recent Development
Table 101. Codagenix Company Details
Table 102. Codagenix Business Overview
Table 103. Codagenix Respiratory Syncytial Virus Vaccines Product
Table 104. Codagenix Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 105. Codagenix Recent Development
Table 106. Intravacc Company Details
Table 107. Intravacc Business Overview
Table 108. Intravacc Respiratory Syncytial Virus Vaccines Product
Table 109. Intravacc Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 110. Intravacc Recent Development
Table 111. Alphavax Company Details
Table 112. Alphavax Business Overview
Table 113. Alphavax Respiratory Syncytial Virus Vaccines Product
Table 114. Alphavax Revenue in Respiratory Syncytial Virus Vaccines Business (2020-2025) & (US$ Million)
Table 115. Alphavax Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Respiratory Syncytial Virus Vaccines Picture
Figure 2. Global Respiratory Syncytial Virus Vaccines Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Syncytial Virus Vaccines Market Share by Type: 2024 VS 2031
Figure 4. Palivizumab Features
Figure 5. RSVpreF PF06928316 Features
Figure 6. RSVPreF3 OA (GSK3844766A) Features
Figure 7. mRNA-1345 Features
Figure 8. Janssen RSV Vaccine Features
Figure 9. ResVax Features
Figure 10. Nirsevimab (MEDI8897) Features
Figure 11. MVA-BN RSV Features
Figure 12. Global Respiratory Syncytial Virus Vaccines Market Size by Application (2020-2031) & (US$ Million)
Figure 13. Global Respiratory Syncytial Virus Vaccines Market Share by Application: 2024 VS 2031
Figure 14. Hospital Case Studies
Figure 15. Clinic Case Studies
Figure 16. Research Institute Case Studies
Figure 17. Respiratory Syncytial Virus Vaccines Report Years Considered
Figure 18. Global Respiratory Syncytial Virus Vaccines Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Respiratory Syncytial Virus Vaccines Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Respiratory Syncytial Virus Vaccines Market Share by Region: 2024 VS 2031
Figure 21. Global Respiratory Syncytial Virus Vaccines Market Share by Players in 2024
Figure 22. Global Top Respiratory Syncytial Virus Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccines as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Respiratory Syncytial Virus Vaccines Revenue in 2024
Figure 24. North America Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 26. United States Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 30. Germany Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Respiratory Syncytial Virus Vaccines Market Share by Region (2020-2031)
Figure 38. China Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 46. Mexico Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Respiratory Syncytial Virus Vaccines Market Share by Country (2020-2031)
Figure 50. Turkey Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Respiratory Syncytial Virus Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Pfizer Inc.Pfizer Inc. Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 55. Merck Sharp & Dohme Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 56. GlaxoSmithKline Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 57. SOBI Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 58. Johnson & Johnson Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 59. Bavarian Nordic Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 60. Novavax Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 61. AstraZeneca Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 62. Moderna Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 63. Codagenix Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 64. Intravacc Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 65. Alphavax Revenue Growth Rate in Respiratory Syncytial Virus Vaccines Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232